Browse > Article

An Improved, Reliable and Practical Kinetic Assay for the Detection of Prekallikrein Activator in Blood Products  

Shin, In-Soo (Blood Product Division. Korea Food & Drug Administration)
Shim, Yun-Bo (Blood Product Division. Korea Food & Drug Administration)
Hong, Choong-Man (Blood Product Division. Korea Food & Drug Administration)
Koh, Hyun-Chul (College of Medicine, Hanyang University)
Lee, Seok-Ho (Blood Product Division. Korea Food & Drug Administration)
Hong, Seung-Hwa (Blood Product Division. Korea Food & Drug Administration)
Publication Information
Archives of Pharmacal Research / v.25, no.4, 2002 , pp. 505-510 More about this Journal
Abstract
An improved kinetic assay for prekallikrein activator (PKA), a potential vasodilator, has been developed to be used as an indicator for quality control during production of human albumin preparations. It consists of two reaction stages. In the first stage, PKA and prekallikrein are incubated at $37^{\circ}C$ for 45 min to allow the transformation into kallikrein. Kallikrein, a serine protease, catalyzes the splitting of p-nitroaniline (pNA) from its substrate H-D-Pro-Phe-Arg-pNA(S-2302). The rate at which pNA is released was measured spectrophotometrically at 405 nm. Prekallikrein, a substrate of PKA was purified by DEAE ion-exchange chromatography and the major potential variations in the assay were optimized; pH 8.0 and 150 mM sodium chloride were chosen to give a proper ionic strength. Reaction times in the range of 10 to 360 min provided linear dose-response curves. The concentration of prekallikrein was adjusted to fall between 1:1 and 1:3 dilutions to generate a linear standard calibration curve. Under the optimized conditions, reproducibility was checked. In a precision test, the coefficient of variation (CV) stayed within ${\pm}4%$ and the dose-response curve showed a good correlation (${r^2}=0.999$). An accuracy test with an international standard of PKA afforded a mean recovery of 97.5%.
Keywords
Prekallikrein Activator; Hypotension; Kinetic Assay;
Citations & Related Records

Times Cited By Web Of Science : 2  (Related Records In Web of Science)
Times Cited By SCOPUS : 1
연도 인용수 순위
1 Domenico, R., Anna, R., and Girolamo, C., Pharmacology of the kallikrein-kinin system. Pharmacol. Res., 35(6), 513-515 (1997)   DOI   ScienceOn
2 Allen, P., Kaplan, M. D., Kusumam, J. and Michael, S.,Pathways for bradykinin formation and inflammatory disease. J. AIlerg. Clin. Immun., 109(2), 195-209 (2002)   DOI   ScienceOn
3 Alving, B. M., Tankersley, D. L., Mason, B. L., Rossi, F., Aronson, D. L. and Finlayson, J. S., Contact-activated factors: contaminants of immunoglobulin preparations with coagulant and vasoactive properties. J. Lab. Clin. Med., 96, 334-346 (1980)   PUBMED
4 Kaplan, A. P. and Austen, K. F., A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J. Exp. Med., 133(4), 696-712 (1971)   DOI   ScienceOn
5 McMillin, C. R., Saito, H, Ratnoff, O. D., and Walton, A. G., The secondary structure of human Hageman factor (factor XII) and its alteration by activating agents. J. Clin. Invest., 54(6), 1312-1322 (1974)   DOI   PUBMED
6 Revak, S. D., Cochrane, C. G., and Griffin, J. H., The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. J. Clin. Invest., 59(6), 1167-75 (1977)   DOI   PUBMED
7 Alving, B. M., Hojima, Y., Pisano, J. J., Mason, B. L., Buckingham, R. E., Mozen, M. M. and Finlayson, J. S., Hypotension associated with prekallikrein activator (Hageman-factor fragments) plasma protein fraction. N. Engl. J. Med., 229, 66-70 (1978)
8 Council of Europe. European Pharmacopoeia, 3rd edition; p. 95, (1997)
9 Hannele T. and Suomela. H., An optimized assay for prekallikrein activator activity in human plasma products. Thromb. Res., 27(1), 35-44 (1982)   DOI   ScienceOn
10 Kuwahara, S. S., Prekallikrein activator (Hageman factor fragment) in human plasma fraction. Transfusion, 20, 433-439 (1980)   DOI   PUBMED   ScienceOn
11 Rob, F., Van, R., Joa, C. B., Donald, M. S., Johan, D. and Jan. A. V. M., Bradykinin-mediated hypotension after infusion of plasma-protein fraction. J. Lab. Clin. Med., 100, 288-295 (1982)   PUBMED
12 Lundbland, J. L., In vitro assay for prekallikrein activator (PKA). Develop. Biol. Standard, 44, 107-114 (1979)
13 Heinonen, J., Peltola, K., Himberg, J.J., and Suomela, H., Hypotensive effect of prekallikrein activator (PKA) in plasma protein fraction (PPF). Develop. Biol. Standard, 48, 129-130 (1981)
14 Radcliffe, R. Nemerson, Y. and Emerson, Y., Mechanism of activation of bovine factor VII. Products of cleavage by factor Xa. J. Biol. Chem., 251(16), 4749-802 (1976)   PUBMED
15 World Health Organization Technical Report Series. Control of albumin and plasma protein fraction. No. 840, Annex 2, Part B. 14. pp. 80-85 (1994)
16 Revak, S. D., Cochrane, C. G., Johnston, A. R. and Hugli, T. E., Structural changes accompanying enzymatic activation of human Hageman factor. J. Clin. Invest., 54(3), 619-27 (1974)   DOI   PUBMED   ScienceOn
17 Kerry, P. J., Curtis, A. D., Catherine, J., and Thomas, D. P., Standardization of prekallikrein activator (PKA): the 1st British Reference Preparation for PKA. British J. Haematol., 52, 275-281 (1982)   DOI   ScienceOn
18 Marley, P. B. and Gilbo, C. M., Temperature sensitivity within the pasteurization temperature range of prekallikrein activator in stable plasma protein solution (SPPS). Transfusion, 21, 320-324 (1981)   DOI   ScienceOn
19 Snape, T. J., Griffith, D., Vallet, L. and Wesley, E. D., The assay of prekallikrein activator in human blood products. Develop. Biol. Standard, 44,115-120 (1979)
20 Bagdasarian, A., Talamo R. C., and Colman, R. W., Simple assay for prekallikrein activators. Immunol. Commun., 2(1), 93-103 (1973)   DOI   PUBMED
21 Tankersley, D. L., Fournel, M. A. and Schroeder, D. D., Kinetics of activation of prekallikrein by prekallikrein activator. Biochemistry, 19, 3121-3127 (1980)   DOI   ScienceOn
22 Luben, G., Quast, U. and Geiger, H., Prekallikrein activator levels and side effects with human albumin preparations. Develop. Biol. Standard, 48, 123-127 (1981)
23 Friberger, P., Gnos, M., Gustavsson, S., Laurell, L. and Claeson, G., A new specific substrate for the determination of plasmin activity. In Scully, M. F. and Kakkar, V. V. (Eds.): Chromogenic peptide substrates: chemistry and clinical usage. Churchill Livingstone, Edinburgh London and New York, pp. 121-127,(1978)
24 Heinonen, J., Peltola, K., Himberg, J. J. and Suomela, H., Vasodilator effect of plasma protein fraction correlates with prekallikrein activator activity. Ann. Thorac. Surg., 33(3), 244-249 (1982)   DOI   PUBMED   ScienceOn
25 Judith, C., Annie, M., Shen, Y. and Andrew, H., Kallikreins and kinins in inflammatory-like events in the reproductive tract. Pharmacol. Res., 35(6), 537-540 (1997)   DOI   ScienceOn
26 Mandle, R. J., Colman, R. W., and Kaplan, A. P., Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc. Natl. Acad. Sci., 73(11), 4179-4183 (1976)   DOI   ScienceOn
27 Griffin, J. H., Role of surface in surface-dependent activation of Hageman factor(blood coagulation factor XII). Proc. Natl. Acad. Sci., 75(4), 1998-2002 (1978)   DOI   ScienceOn
28 Kaplan, A. P., Initiation of the intrinsic coagulation and fibrinolytic pathways of man: the role of surfaces, Hageman factor, prekallikrein, high molecular weight kininogen, and factor XI. Prog. Hemost. Thromb., 4, 127-75 (1978)   PUBMED
29 Kaplan, A. P., Kay, A. B. and Austen, K. F., A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J. Exp. Med., 135(1), 81-97 (1972)   DOI   ScienceOn
30 Siv, F., Nils-Ove, H., Halvard G. and Kjell, B., Contact activation factors in plasma from women on estrogen replacement therapy after ovariohysterectomy. Thrombosis Research, 93, 161-170 (1999)   DOI   ScienceOn
31 Turner, P. J., Young, I. F., Marley, P. B., Herrington, R. W. and Schiff, P., Albumin solutions- Their production and quality control. Develop. Biol. Standard, 67, 119-127 (1987)
32 Kaplan, A. P., and Austen, K. F., A pre-albumin activator of prekallikrein. J. Immunol., 105(4), 802-811 (1970)   PUBMED
33 Yasda, J., Ueno, G., Kuratsuka, K., Homma, R., Hara, S., Kazama, M. and Ito, H., Japanese minimum requirements for albumin preparations: recent amendments and current problems. Develop. Biol. Standard., 48, 143-152 (1981)